Thomas Deitrich, who serves as President and Chief Executive Officer of Itron, Inc. (NASDAQ:ITRI), executed a transaction on May 26, 2026, selling 862 shares of the company's common stock.
The sale was completed at an individual price point of $84.3667 per share, resulting in a total divestment value of $72,724. This transaction is noted as being automatically executed to cover tax withholding obligations that arose from the vesting of a restricted stock unit award.
The sale occurs against a backdrop where Itron's stock has experienced a decline of 26% over the preceding year. However, while market performance shows this dip, an InvestingPro analysis suggests that the stock may still be undervalued when considering current valuation levels.
Following the disposal of these shares, Mr. Deitrich maintains direct ownership of 368,679 shares of Itron common stock. Furthermore, his indirect holdings are reported at 25,000 shares held through a trust arrangement.
Recent Financial Performance and Analyst Adjustments
In separate company news, Itron Inc. released financial results for the first quarter of 2026 that surpassed market expectations in key areas. The firm reported earnings per share (EPS) of $1.49, which exceeded the forecasted figure of $1.23. Revenue also performed above projections, totaling $587 million when analysts had anticipated a figure of $572.09 million.
Despite these positive operational outcomes reported in Q1 2026, the financial analysis firm Roth/MKM adjusted its price target for Itron. The target was lowered from $150 to $136, although they maintained their Buy rating on the stock. This downward revision of the price target is specifically attributed by the analysts to a more subdued near-term revenue growth trajectory. They further noted that this anticipated slowdown in growth is influenced by complex projects and temporary regulatory dynamics.
Market Context and Valuation Indicators
These varied developments highlight ongoing, detailed investor interest and scrutiny regarding Itron's overall performance and its strategic direction moving forward. Investors seeking deeper insights into the company’s financial stability and valuation metrics can review data points such as the P/E ratio of 13.6. Comprehensive research reports are available to provide a more thorough view of Itron’s financial health.
The recent earnings beat provides a positive signal, but the analyst adjustment and the CEO's stock sale introduce elements of caution regarding immediate valuation expectations. The market must weigh strong quarterly performance against anticipated near-term headwinds in revenue growth.